| HOME >> MEDICINE >> TECHNOLOGY |
Vibativ (telavancin; Theravance/Astellas Pharma) 63
Zienam/Primaxin (imipenem/cilastatin; Merck & Co.) 66
Doribax/Finibax (doripenem; Johnson & Johnson/Shionogi & Co.) 69
Invanz (ertapenem; Merck & Co.) 72
Bibliography 76
Journal papers 76
Websites 77
Datamonitor reports 78
Appendix A – Market Assumptions 79
New product launches 79
Patent expiries 79
Data definitions, limitations and assumptions 80
Forecast methodology 81
Appendix B 82
Contributing experts 82
Conferences attended 82
Report methodology 82
About Datamonitor 82
Disclaimer 85
TABLE OF FIGURES
Figure 1: Antibacterial sales ($m) in the seven major markets, by type of product (marketed versus pipeline), 2005–19 12
Figure 2: Antibacterial sales ($m) and CAGR (%) in the seven major markets, by region, 2005–19 15
Figure 3: Antibacterial sales ($m) in the seven major markets, by country, 2005–19 16
Figure 4: Antibacterial sales ($m) in the seven major markets, by drug class, 2005–19 21
Figure 5: Sales of key antibacterial brands/molecules in the seven major markets ($m), 2009 and 2019 23
Figure 6: Comparison of fluoroquinolone class forecasts in the seven major markets, 2005–19 28
Figure 7: Comparison of antibacterial market forecasts in the seven major markets, 2005–19 29
Figure 8: Rest of the World versus seven major market sales split for the antibacterials market, 2009 31
Figure 9: Indexed annual sales of the antibacterials market in small and emerging markets, 2005–09 32
Figure 10: 2009 and updated sales forecast for Levaquin, Cravit, and Tavanic in the seven major markets ($m), 2009–19 43
Figure 11: 2009 and updated sales forecast for Zosyn and Tazocin in the seven major markets ($m), 2009–19 45
F
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |